Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Closebax SD is a topical dermocosmetic product line developed by Synchroline (a brand of General Topics s.r.l.) specifically designed for the management of seborrheic dermatitis and severe dandruff. The formulation is available in various forms, including a shampoo and a cream, and utilizes a multi-targeted approach to address the underlying causes of seborrheic conditions. It typically contains a combination of antifungal agents such as **climbazole** and **piroctone olamine**, which inhibit the growth of *Malassezia* yeast, a primary contributor to seborrheic dermatitis. Additionally, it incorporates **triethyl citrate** to inhibit the lipase enzymes that break down sebum into irritating fatty acids, **zinc lactate** for sebum regulation, and **salicylic acid** for its keratolytic properties to facilitate the removal of scales and crusts. The product aims to reduce inflammation, itching, and desquamation while restoring the scalp's natural balance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Closebax SD.